Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?

Detalhes bibliográficos
Autor(a) principal: Morgado, Fernanda N.
Data de Publicação: 2016
Outros Autores: Schubach, Armando O., Pimentel, Maria Inês, Lyra, Marcelo R., Vasconcellos, Érica C.F., Valete-Rosalino, CM, Conceição-Silva, Fátima
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.1371/journal.pone.0162764
Resumo: Fungus of the Sporothrix schenckii complex can produce skin lesions in humans, commonly lymphocutaneous (LC) and fixed (F) forms of sporotrichosis. Some authors have suggested that clinical forms are influenced by differences in virulence and genetic profile of isolates. But little is known about the role of immune response in determining the clinical outcome of sporotrichosis. To verify the profile of systemic and in situ IFN-ã and IL-10 expression in sporotrichosis patients, and consequently to detect any difference between the two compartments and/or clinical presentation, we quantified the number of IFN-ã and IL-10 producer peripheral blood mononuclear cells stimulated with S. schenckii antigen (Ss-Ag) by Elispot, and quantified cytokines expression by in situ immunohistochemistry in the same patient. Three groups were formed: 1- LC (n = 9); 2- F (n = 10); 3- healthy individuals (n = 14). All sporotrichosis patients produced high amounts of systemic IFN- ã when compared to uninfected individuals. No differences were observed between LC and F groups. Regarding in situ IL-10 expression, a difference between LC and F groups was observed: LC lesions presented higher amounts of IL-10 than F lesions differently from systemic IL-10 which showed similarities. Our data suggests that LC lesions present higher IL-10 expression which could be related to regulatory mechanisms for compensating the tissue injury, however favoring fungal persistence in the lesions. Surprisingly, there were no differences in systemic and in situ IFN- ã expression between CL and F patients, although it was significantly higher expressed in these patients than in healthy individuals.
id RCAP_6944dc71981a02e84afaa0ceb43aaae2
oai_identifier_str oai:run.unl.pt:10362/36687
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?Medicine(all)Biochemistry, Genetics and Molecular Biology(all)Agricultural and Biological Sciences(all)Fungus of the Sporothrix schenckii complex can produce skin lesions in humans, commonly lymphocutaneous (LC) and fixed (F) forms of sporotrichosis. Some authors have suggested that clinical forms are influenced by differences in virulence and genetic profile of isolates. But little is known about the role of immune response in determining the clinical outcome of sporotrichosis. To verify the profile of systemic and in situ IFN-ã and IL-10 expression in sporotrichosis patients, and consequently to detect any difference between the two compartments and/or clinical presentation, we quantified the number of IFN-ã and IL-10 producer peripheral blood mononuclear cells stimulated with S. schenckii antigen (Ss-Ag) by Elispot, and quantified cytokines expression by in situ immunohistochemistry in the same patient. Three groups were formed: 1- LC (n = 9); 2- F (n = 10); 3- healthy individuals (n = 14). All sporotrichosis patients produced high amounts of systemic IFN- ã when compared to uninfected individuals. No differences were observed between LC and F groups. Regarding in situ IL-10 expression, a difference between LC and F groups was observed: LC lesions presented higher amounts of IL-10 than F lesions differently from systemic IL-10 which showed similarities. Our data suggests that LC lesions present higher IL-10 expression which could be related to regulatory mechanisms for compensating the tissue injury, however favoring fungal persistence in the lesions. Surprisingly, there were no differences in systemic and in situ IFN- ã expression between CL and F patients, although it was significantly higher expressed in these patients than in healthy individuals.Instituto de Higiene e Medicina Tropical (IHMT)RUNMorgado, Fernanda N.Schubach, Armando O.Pimentel, Maria InêsLyra, Marcelo R.Vasconcellos, Érica C.F.Valete-Rosalino, CMConceição-Silva, Fátima2018-05-11T22:09:18Z2016-09-012016-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.1371/journal.pone.0162764eng1932-6203PURE: 3067880http://www.scopus.com/inward/record.url?scp=84990946220&partnerID=8YFLogxKhttps://doi.org/10.1371/journal.pone.0162764info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:20:16Zoai:run.unl.pt:10362/36687Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:30:38.321580Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
title Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
spellingShingle Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
Morgado, Fernanda N.
Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)
title_short Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
title_full Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
title_fullStr Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
title_full_unstemmed Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
title_sort Is there any difference between the in situ and systemic IL-10 and IFN-ã production when clinical forms of cutaneous sporotrichosis are compared?
author Morgado, Fernanda N.
author_facet Morgado, Fernanda N.
Schubach, Armando O.
Pimentel, Maria Inês
Lyra, Marcelo R.
Vasconcellos, Érica C.F.
Valete-Rosalino, CM
Conceição-Silva, Fátima
author_role author
author2 Schubach, Armando O.
Pimentel, Maria Inês
Lyra, Marcelo R.
Vasconcellos, Érica C.F.
Valete-Rosalino, CM
Conceição-Silva, Fátima
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Higiene e Medicina Tropical (IHMT)
RUN
dc.contributor.author.fl_str_mv Morgado, Fernanda N.
Schubach, Armando O.
Pimentel, Maria Inês
Lyra, Marcelo R.
Vasconcellos, Érica C.F.
Valete-Rosalino, CM
Conceição-Silva, Fátima
dc.subject.por.fl_str_mv Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)
topic Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)
description Fungus of the Sporothrix schenckii complex can produce skin lesions in humans, commonly lymphocutaneous (LC) and fixed (F) forms of sporotrichosis. Some authors have suggested that clinical forms are influenced by differences in virulence and genetic profile of isolates. But little is known about the role of immune response in determining the clinical outcome of sporotrichosis. To verify the profile of systemic and in situ IFN-ã and IL-10 expression in sporotrichosis patients, and consequently to detect any difference between the two compartments and/or clinical presentation, we quantified the number of IFN-ã and IL-10 producer peripheral blood mononuclear cells stimulated with S. schenckii antigen (Ss-Ag) by Elispot, and quantified cytokines expression by in situ immunohistochemistry in the same patient. Three groups were formed: 1- LC (n = 9); 2- F (n = 10); 3- healthy individuals (n = 14). All sporotrichosis patients produced high amounts of systemic IFN- ã when compared to uninfected individuals. No differences were observed between LC and F groups. Regarding in situ IL-10 expression, a difference between LC and F groups was observed: LC lesions presented higher amounts of IL-10 than F lesions differently from systemic IL-10 which showed similarities. Our data suggests that LC lesions present higher IL-10 expression which could be related to regulatory mechanisms for compensating the tissue injury, however favoring fungal persistence in the lesions. Surprisingly, there were no differences in systemic and in situ IFN- ã expression between CL and F patients, although it was significantly higher expressed in these patients than in healthy individuals.
publishDate 2016
dc.date.none.fl_str_mv 2016-09-01
2016-09-01T00:00:00Z
2018-05-11T22:09:18Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.1371/journal.pone.0162764
url https://doi.org/10.1371/journal.pone.0162764
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1932-6203
PURE: 3067880
http://www.scopus.com/inward/record.url?scp=84990946220&partnerID=8YFLogxK
https://doi.org/10.1371/journal.pone.0162764
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137930626727936